Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.41 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4844424 | 1.00 | PARP1 (0.46) | PARP1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8116046 | 0.89 | CHEK2 (0.44) | PARP1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31218714 | 0.88 | KDM4E (0.45) | PARP1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL31634907 | 0.86 | ALDH1A1 (0.52) | PARP1ALDH1A1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL4710881 | 0.84 | PARP1 (0.48) | PARP1NR1H2NR1H3 | |
| SCHEMBL873250 | 0.82 | PARP1 (0.46) | PARP1NR1H2NR1H3 | |
| SCHEMBL27904548 | 0.82 | PARP1 (0.46) | PARP1NR1H2NR1H3 | |
| SCHEMBL31476896 | 0.82 | PARP1 (0.39) | PARP1ALDH1A1CHEK2GPR119NR1H2 | |
| SCHEMBL6609250 | 0.82 | CHEK2 (0.56) | ALDH1A1SMN1; SMN2CHEK2 | |
| SCHEMBL873458 | 0.81 | PARP1 (0.54) | PARP1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405217-B2 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-07-29 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-20070167457-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC | 2007-07-19 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7166608-B2 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| US-20040242575-A1 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242575-A1 | N-aroyl piperazine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, CNR1 | PARP1 3197/4885MEN1 2853/4885ALDH1A1 883/4885 |
| US-20070167457-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | PARP1 3413/4885MEN1 3090/4885ALDH1A1 2131/4885 |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | PARP1 2330/4885MEN1 4511/4885ALDH1A1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.